Comparative effects of conventional vs. novel hormone replacement therapy on blood pressure in postmenopausal women

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Menopause is commonly characterized by an increase in blood pressure. Higher blood pressure may partially explain the elevated risk for cardiovascular events observed in postmenopausal women. There is a graded relationship between blood pressure and cardiovascular risk which extends to levels of blood pressure well below 140/90 mmHg, the classical established blood pressure limit for the diagnosis of hypertension. Despite this knowledge and the wide availability of consensus treatment guidelines for hypertension, high blood pressure remains untreated or poorly treated in many postmenopausal patients. It is clear that novel and innovative population strategies for lowering blood pressure in postmenopausal women are warranted. Clinical trials suggest that oral estrogen administration may produce either a neutral effect or a small increase in blood pressure in postmenopausal women. Transdermal estrogen administration has not been studied as extensively but may produce a decrease in blood pressure. The mechanisms for the differences observed between oral and transdermal estrogen have not been completely elucidated. Drospirenone (DRSP) is a novel progestin with aldosterone receptor antagonist activity that has been developed for hormone therapy as DRSP/17β-estradiol (DRSP/E2). In several clinical trials, DRSP/E2 has demonstrated a significant antihypertensive effect as well an additive effect when combined with existing antihypertensive therapy. Despite the wide availability of treatment guidelines, a wide array of antihypertensive agents, and the introduction of hormone replacement therapy that can lower blood pressure, optimizing blood pressure control remains a serious issue confronting the physician who cares for the postmenopausal woman.

Original languageEnglish
Pages (from-to)66-70
Number of pages5
JournalClimacteric
Volume12
Issue numberSUPPL. 1
DOIs
StatePublished - Dec 1 2009

Fingerprint

Hormone Replacement Therapy
Blood Pressure
Antihypertensive Agents
Hypertension
Estrogens
Clinical Trials
Guidelines
Cutaneous Administration
Mineralocorticoid Receptor Antagonists
Progestins
Therapeutics
Menopause
Oral Administration
Estradiol
Hormones
Physicians
drospirenone

Keywords

  • ALDOSTERONE
  • DROSPIRENONE
  • HORMONE REPLACEMENT
  • HYPERTENSION
  • MENOPAUSE

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Medicine(all)

Cite this

Comparative effects of conventional vs. novel hormone replacement therapy on blood pressure in postmenopausal women. / Preston, Richard A.

In: Climacteric, Vol. 12, No. SUPPL. 1, 01.12.2009, p. 66-70.

Research output: Contribution to journalArticle

@article{32ec5c800ffa489f8a98140d1231d7eb,
title = "Comparative effects of conventional vs. novel hormone replacement therapy on blood pressure in postmenopausal women",
abstract = "Menopause is commonly characterized by an increase in blood pressure. Higher blood pressure may partially explain the elevated risk for cardiovascular events observed in postmenopausal women. There is a graded relationship between blood pressure and cardiovascular risk which extends to levels of blood pressure well below 140/90 mmHg, the classical established blood pressure limit for the diagnosis of hypertension. Despite this knowledge and the wide availability of consensus treatment guidelines for hypertension, high blood pressure remains untreated or poorly treated in many postmenopausal patients. It is clear that novel and innovative population strategies for lowering blood pressure in postmenopausal women are warranted. Clinical trials suggest that oral estrogen administration may produce either a neutral effect or a small increase in blood pressure in postmenopausal women. Transdermal estrogen administration has not been studied as extensively but may produce a decrease in blood pressure. The mechanisms for the differences observed between oral and transdermal estrogen have not been completely elucidated. Drospirenone (DRSP) is a novel progestin with aldosterone receptor antagonist activity that has been developed for hormone therapy as DRSP/17β-estradiol (DRSP/E2). In several clinical trials, DRSP/E2 has demonstrated a significant antihypertensive effect as well an additive effect when combined with existing antihypertensive therapy. Despite the wide availability of treatment guidelines, a wide array of antihypertensive agents, and the introduction of hormone replacement therapy that can lower blood pressure, optimizing blood pressure control remains a serious issue confronting the physician who cares for the postmenopausal woman.",
keywords = "ALDOSTERONE, DROSPIRENONE, HORMONE REPLACEMENT, HYPERTENSION, MENOPAUSE",
author = "Preston, {Richard A}",
year = "2009",
month = "12",
day = "1",
doi = "10.1080/13697130902775788",
language = "English",
volume = "12",
pages = "66--70",
journal = "Climacteric",
issn = "1369-7137",
publisher = "Informa Healthcare",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Comparative effects of conventional vs. novel hormone replacement therapy on blood pressure in postmenopausal women

AU - Preston, Richard A

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Menopause is commonly characterized by an increase in blood pressure. Higher blood pressure may partially explain the elevated risk for cardiovascular events observed in postmenopausal women. There is a graded relationship between blood pressure and cardiovascular risk which extends to levels of blood pressure well below 140/90 mmHg, the classical established blood pressure limit for the diagnosis of hypertension. Despite this knowledge and the wide availability of consensus treatment guidelines for hypertension, high blood pressure remains untreated or poorly treated in many postmenopausal patients. It is clear that novel and innovative population strategies for lowering blood pressure in postmenopausal women are warranted. Clinical trials suggest that oral estrogen administration may produce either a neutral effect or a small increase in blood pressure in postmenopausal women. Transdermal estrogen administration has not been studied as extensively but may produce a decrease in blood pressure. The mechanisms for the differences observed between oral and transdermal estrogen have not been completely elucidated. Drospirenone (DRSP) is a novel progestin with aldosterone receptor antagonist activity that has been developed for hormone therapy as DRSP/17β-estradiol (DRSP/E2). In several clinical trials, DRSP/E2 has demonstrated a significant antihypertensive effect as well an additive effect when combined with existing antihypertensive therapy. Despite the wide availability of treatment guidelines, a wide array of antihypertensive agents, and the introduction of hormone replacement therapy that can lower blood pressure, optimizing blood pressure control remains a serious issue confronting the physician who cares for the postmenopausal woman.

AB - Menopause is commonly characterized by an increase in blood pressure. Higher blood pressure may partially explain the elevated risk for cardiovascular events observed in postmenopausal women. There is a graded relationship between blood pressure and cardiovascular risk which extends to levels of blood pressure well below 140/90 mmHg, the classical established blood pressure limit for the diagnosis of hypertension. Despite this knowledge and the wide availability of consensus treatment guidelines for hypertension, high blood pressure remains untreated or poorly treated in many postmenopausal patients. It is clear that novel and innovative population strategies for lowering blood pressure in postmenopausal women are warranted. Clinical trials suggest that oral estrogen administration may produce either a neutral effect or a small increase in blood pressure in postmenopausal women. Transdermal estrogen administration has not been studied as extensively but may produce a decrease in blood pressure. The mechanisms for the differences observed between oral and transdermal estrogen have not been completely elucidated. Drospirenone (DRSP) is a novel progestin with aldosterone receptor antagonist activity that has been developed for hormone therapy as DRSP/17β-estradiol (DRSP/E2). In several clinical trials, DRSP/E2 has demonstrated a significant antihypertensive effect as well an additive effect when combined with existing antihypertensive therapy. Despite the wide availability of treatment guidelines, a wide array of antihypertensive agents, and the introduction of hormone replacement therapy that can lower blood pressure, optimizing blood pressure control remains a serious issue confronting the physician who cares for the postmenopausal woman.

KW - ALDOSTERONE

KW - DROSPIRENONE

KW - HORMONE REPLACEMENT

KW - HYPERTENSION

KW - MENOPAUSE

UR - http://www.scopus.com/inward/record.url?scp=73949108428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949108428&partnerID=8YFLogxK

U2 - 10.1080/13697130902775788

DO - 10.1080/13697130902775788

M3 - Article

C2 - 19811245

AN - SCOPUS:73949108428

VL - 12

SP - 66

EP - 70

JO - Climacteric

JF - Climacteric

SN - 1369-7137

IS - SUPPL. 1

ER -